Pfizer Investigational Site
Ahmedabad, Gujarat, 380 015, India
NCT Number: NCT00860119
This study tests the assumption that the bioavailability of alprazolam from a new sublingual formulation is the same as that from a standard orally administered tablet.
Looking for future studies?
Notify Me21 year–55 year
All sexes
Interventional
Phase 1
Ahmedabad, Gujarat, 380 015, India
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
1 mg alprazolam sublingual tablet, given as a single dose to each subject
1 mg alprazolam immediate release oral tablet, given as a single dose to each subject
Other names: Xanax
Time frame: 11 days
Time frame: 11 days
Time frame: 11 days
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Open-Label, Randomized, Single-Dose, 2-Way Crossover Pivotal Bioequivalence Study Comparing Alprazolam Immediate Release (IR) Tablets (Administered Orally) And Alprazolam Sublingual (SL) Tablets (Administered Sublingually)
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07629414
Healthy, Heat Stress Disorders
Shreveport, Louisiana, United States
View Trial DetailsNCT07531628
Healthy
Hangzhou, China
View Trial DetailsNCT01866852
Healthy
Bethesda, Maryland, United States
View Trial DetailsNCT06354686
Healthy
Tallahassee, Florida, United States
View Trial Details